European Application Submitted for Cilta-cel in Relapsed and Lenalidomide-Refractory Myeloma
The Type II variation application for ciltacabtagene autoleucel in adult patients with relapsed and lenalidomide-refractory multiple myeloma is supported by data from the phase 3 CARTITUDE-4 trial.
A version of this article originally appeared on our sister site, OncLive.
Sen Zhuang, MD, PhD
The European Medicines Agency (EMA) has announced that it received a Type II variation application for the approval of ciltacabtagene autoleucel (Carvykti; cilta-cel) in adult patients with relapsed and lenalidomide (Revlimid)-refractory multiple myeloma (MM).1
The Johnson & Johnson/Legend Biotech cell therapy has its application supported by findings from the phase 3 CARTITUDE-4 trial (NCT04181827), which has indicated—in leaked data from an abstract that was slated for presentation at the 2023 European Hematology Association Hybrid Congress—that the CAR T-cell therapy reduced the risk of progressive disease or death vs pomalidomide (Pomalyst; Bristol-Myers Squibb), bortezomib (Velcade; Takeda), and dexamethasone (a combination approach commonly referred to as PVd); or daratumumab (Darzalex; Janssen), pomalidomide, and dexamethasone (a combination approach commonly refrred to as DPd) in those with relapsed or refractory disease who received 1 to 3 prior lines of therapy.2
In the data, the median progression-free survival (PFS) was not yet reached with cilta-cel compared with 12 months with the control regimen. Additionally, the 12-month PFS rates were 76% in the treatment arm and 49% in the control arm, with the CAR T-cell therapy eliciting an overall response rate of 88%, compared with 67% for the control.
Of note, though, is that 73% of patients who received cilta-cel had a complete response to treatment compared with only 22% who were given the control. These data are anticipated to be shared in a special session at the upcoming American Society of Clinical Oncology Annual Meeting.
Sen Zhuang, MD, PhD, vice president of clinical research and development at Janssen Research & Development, said in a press release that “this submission is a testament to our relentless commitment to advance science, transform outcomes, challenge what a MM diagnosis means for patients, and ultimately, work toward our goal of one day curing this complex disease."
READ MORE: CARTITUDE-4 Data Leak Reveals Promising Results for Cilta-Cel in Multiple Myeloma
CARTITUDE-4 enrolled patients with MM who had measurable disease at screening, previously received 1 to 3 lines of therapy that included a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), and had evidence of progressive disease on or within 6 months of their last regimen by International Myeloma Working Group.3 These individuals also needed to be refractory to lenalidomide and meet all prespecified clinical laboratory values.
If they previously received CAR T-cell therapy or any BCMA-targeted treatment or are experiencing any ongoing toxicity from prior treatment that has not resolved to baseline or grade 1 or less, they were excluded. Other exclusion criteria included having received a monoclonal antibody treatment in 21 days, cytotoxic therapy within 2 weeks, a PI in 2 weeks, an IMiD in 1 week, or a cumulative dose of corticosteroids equivalent to 70 mg of prednisone in the week before randomization on the trial.
Those randomly assigned to the investigative arm received at least 1 cycle of bridging therapy with PVd or DPd, with additional cycles permitted based on clinical status and availability of cilta-cel. They also received a conditioning regimen comprised of 300 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine for 3 days. The CAR T-cell therapy was then administered via infusion at 0.75 x 106 CAR+ viable T cells/kg.
Those in the control arm received standard treatment with either PVd or DPd. Those who had PVd were given pomalidomide at 4 mg on days 1 to 14 of each 21-day cycle, bortezomib at 1.3 mg/m2 on days 1, 4, 8, and 11 of cycles 1 through 8 and on days 1 and 8 of cycle 9 and thereafter, and dexamethasone at 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12 of cycles 1 through 8 and on days 1, 2, 8, and 9 for cycle 9 and beyond. Those given DPd received daratumumab at a weekly dose of 1800 mg on days 1, 8, 15, and 22 on cycles 1 and 2 and then every 2 weeks on days 1 and 15 for cycles 3 to 6 and then every 4 weeks on day 1 for cycle 7 and beyond; plus 4 mg of pomalidomide on days 1 to 21 for cycle 1 and on; and 40 mg of dexamethasone weekly on days 1, 8, 15, and 22 for cycle 1 and on.
In January 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the trial met its primary end point at the first prespecified interim analysis.4 The independent data monitoring committee recommended the unblinding of the trial because of this milestone. Participants are expected to continue to be followed for primary, secondary, and exploratory end points for the duration of the trial.
